What Target (TGT)'s Activist Pressure and New Family Brand Partnership Means For Shareholders

• In late December 2025, Toms Capital Investment Management disclosed an investment in Target Corporation, adding activist pressure as the retailer confronts a prolonged sales slump and leadership transition, while kids’ vitamin brand First Day announced its first-ever retail launch at select Target stores and on Target.com with nine gummy products priced between US$29.99 and US$39.99.
• This combination of activist involvement and new brand partnerships underscores how Target’s turnaround efforts now span both boardroom influence and refreshed in-store offerings aimed at budget-conscious families.
• With Toms Capital pressing for change at Target, we’ll now examine how activist influence could reshape the company’s investment narrative and outlook.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Target Investment Narrative Recap

To own Target today, you need to believe its turnaround can translate weak sales trends and leadership change into a more compelling value and growth story, without eroding profitability too far. In the near term, the most important catalyst is whether activist pressure from Toms Capital and the new CEO can drive credible operational and merchandising changes, while the biggest risk is that fixing price gaps, stores and assortments proves more costly and slower than expected. The latest announcements do not materially change that risk reward balance yet.

The First Day launch at select Target stores and on Target.com fits squarely into Target’s long running focus on exclusive and owned style offerings that appeal to families. While this kids and women’s vitamin rollout is small in financial terms, it shows how Target is still trying to refresh traffic drivers and basket size, which matters if management and activists focus on merchandising upgrades as a core lever in the turnaround.

Yet behind the potential upside, investors should be aware that higher labor, merchandising and store investments could pressure earnings if...

Read the full narrative on Target (it's free!)

Target’s narrative projects $110.5 billion revenue and $3.7 billion earnings by 2028. This requires 1.4% yearly revenue growth and a $0.5 billion earnings decrease from $4.2 billion today.

Uncover how Target's forecasts yield a $96.52 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Twenty two members of the Simply Wall St Community value Target between US$73.76 and US$141.08, reflecting a wide range of expectations. When you set those views against the current activist involvement and operational reset, it is worth exploring how different assumptions about margins and store level investment could shape the company’s future performance.

Explore 22 other fair value estimates on Target - why the stock might be worth as much as 40% more than the current price!

Build Your Own Target Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Target research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Target research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Target's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com